(CAL) Caleres - Overview
Sector: Consumer Cyclical | Industry: Apparel Retail | Exchange: NYSE (USA) | Market Cap: 466m USD | Total Return: -16.8% in 12m
Avg Turnover: 7.27M
EPS Trend: -83.4%
Qual. Beats: -4
Rev. Trend: -85.9%
Qual. Beats: 0
Warnings
High Debt/EBITDA (17.2) with thin interest coverage (1.1)
Extended 1w Choppy
Tailwinds
No distinct edge detected
Caleres, Inc. is a global footwear company operating through two primary segments: Famous Footwear and Brand Portfolio. The company manages a diverse ecosystem of owned, licensed, and third-party brands, including Allen Edmonds, Sam Edelman, and Dr. Scholl’s. Its business model integrates vertical operations, encompassing design, sourcing, manufacturing, and distribution across retail, wholesale, and e-commerce channels.
The company operates within the footwear retail sector, a market characterized by high inventory turnover requirements and sensitivity to consumer discretionary spending trends. Caleres utilizes a dual-track strategy, leveraging the high-volume traffic of Famous Footwear stores alongside the higher-margin potential of its proprietary brand portfolio. For a deeper look into these financial metrics, ValueRay offers additional insights.
Headquartered in St. Louis and founded in 1878, Caleres maintains an extensive digital footprint through brand-specific e-commerce sites and distributes products to national chains, department stores, and independent retailers. This multi-channel approach allows the firm to capture diverse consumer segments ranging from athletic performance to luxury dress footwear.
- Famous Footwear comparable store sales drive total retail revenue growth
- Inventory management and supply chain costs impact consolidated gross margins
- Consumer discretionary spending shifts influence demand for fashion and athletic brands
- Wholesale distribution growth through department stores and online retailers scales volume
- Brand Portfolio performance depends on successful integration of licensed and owned labels
| Net Income: -7.05m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -1.46 > 1.0 |
| NWC/Revenue: 0.62% < 20% (prev 2.89%; Δ -2.26% < -1%) |
| CFO/TA 0.05 > 3% & CFO 97.3m > Net Income -7.05m |
| Net Debt (1.46b) to EBITDA (84.5m): 17.24 < 3 |
| Current Ratio: 1.02 > 1.5 & < 3 |
| Outstanding Shares: last quarter (32.6m) vs 12m ago 0.06% < -2% |
| Gross Margin: 42.96% > 18% (prev 0.45%; Δ 4.25k% > 0.5%) |
| Asset Turnover: 142.9% > 50% (prev 143.7%; Δ -0.82% > 0%) |
| Interest Coverage Ratio: 1.08 > 6 (EBITDA TTM 84.5m / Interest Expense TTM 18.5m) |
| A: 0.01 (Total Current Assets 862.8m - Total Current Liabilities 845.5m) / Total Assets 1.97b |
| B: 0.21 (Retained Earnings 421.2m / Total Assets 1.97b) |
| C: 0.01 (EBIT TTM 19.9m / Avg Total Assets 1.93b) |
| D: 0.30 (Book Value of Equity 403.0m / Total Liabilities 1.36b) |
| Altman-Z'' = 1.14 = BB |
| DSRI: 0.86 (Receivables 147.2m/169.6m, Revenue 2.76b/2.72b) |
| GMI: 1.04 (GM 42.96% / 44.73%) |
| AQI: 0.68 (AQ_t 0.17 / AQ_t-1 0.25) |
| SGI: 1.01 (Revenue 2.76b / 2.72b) |
| TATA: -0.05 (NI -7.05m - CFO 97.3m) / TA 1.97b) |
| Beneish M = -3.34 (Cap -4..+1) = AA |
As of May 26, 2026, the stock is trading at USD 13.50 with a total of 671,600 shares traded.
Over the past week, the price has changed by +21.95%,
over one month by +0.60%,
over three months by +14.36% and
over the past year by -16.76%.
Caleres has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy CAL.
- StrongBuy: 1
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 15 | 11.1% |
P/E Forward = 8.2781
P/S = 0.1691
P/B = 0.7378
P/EG = 0.8213
Revenue TTM = 2.76b USD
EBIT TTM = 19.9m USD
EBITDA TTM = 84.5m USD
Long Term Debt = 467.6m USD (estimated: total debt 891.1m - short term 423.5m)
Short Term Debt = 423.5m USD (from shortTermDebt, last quarter)
Debt = 1.49b USD (from shortLongTermDebtTotal, last quarter) + Leases 594.6m
Net Debt = 1.46b USD (calculated: Debt 1.49b - CCE 29.8m)
Enterprise Value = 1.92b USD (466.3m + Debt 1.49b - CCE 29.8m)
Interest Coverage Ratio = 1.08 (Ebit TTM 19.9m / Interest Expense TTM 18.5m)
EV/FCF = 73.64x (Enterprise Value 1.92b / FCF TTM 26.1m)
FCF Yield = 1.36% (FCF TTM 26.1m / Enterprise Value 1.92b)
FCF Margin = 0.95% (FCF TTM 26.1m / Revenue TTM 2.76b)
Net Margin = -0.26% (Net Income TTM -7.05m / Revenue TTM 2.76b)
Gross Margin = 42.96% ((Revenue TTM 2.76b - Cost of Revenue TTM 1.57b) / Revenue TTM)
Gross Margin QoQ = 41.77% (prev 41.76%)
Tobins Q-Ratio = 0.98 (Enterprise Value 1.92b / Total Assets 1.97b)
Interest Expense / Debt = 1.24% (Interest Expense 18.5m / Debt 1.49b)
Taxrate = 21.0% (US default 21%)
NOPAT = 15.7m (EBIT 19.9m * (1 - 21.00%))
Current Ratio = 1.02 (Total Current Assets 862.8m / Total Current Liabilities 845.5m)
Debt / Equity = 2.47 (Debt 1.49b / totalStockholderEquity, last quarter 601.9m)
Debt / EBITDA = 17.24 (Net Debt 1.46b / EBITDA 84.5m)
Debt / FCF = 55.78 (Net Debt 1.46b / FCF TTM 26.1m)
Total Stockholder Equity = 609.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.37% (Net Income -7.05m / Total Assets 1.97b)
RoE = -1.16% (Net Income TTM -7.05m / Total Stockholder Equity 609.3m)
RoCE = 1.85% (EBIT 19.9m / Capital Employed (Equity 609.3m + L.T.Debt 467.6m))
RoIC = 1.04% (NOPAT 15.7m / Invested Capital 1.51b)
WACC = 3.60% (E(466.3m)/V(1.95b) * Re(11.93%) + D(1.49b)/V(1.95b) * Rd(1.24%) * (1-Tc(0.21)))
Discount Rate = 11.93% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -58.43 | Cagr: -1.71%
[DCF] Terminal Value 73.10% ; FCFF base≈36.8m ; Y1≈32.3m ; Y5≈26.1m
[DCF] Fair Price = N/A (negative equity: EV 418.7m - Net Debt 1.46b = -1.04b; debt exceeds intrinsic value)
EPS Correlation: -83.38 | EPS CAGR: -37.82% | SUE: -1.79 | # QB: -4
Revenue Correlation: -85.89 | Revenue CAGR: -2.49% | SUE: 0.56 | # QB: 0
EPS current Quarter (2026-07-31): EPS=0.38 | Chg30d=-0.86% | Revisions=+20% | Analysts=1
EPS current Year (2027-01-31): EPS=1.56 | Chg30d=+1.96% | Revisions=-20% | GrowthEPS=+31.4% | GrowthRev=+4.3%
EPS next Year (2028-01-31): EPS=2.14 | Chg30d=+1.42% | Revisions=-20% | GrowthEPS=+36.9% | GrowthRev=+2.4%
[Analyst] Revisions Ratio: +20%